NEW YORK, Jan. 11, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation (“Ophthotech”) (NASDAQ:OPHT) between May 11, 2015 and December 12, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Micholle v. Ophthotech Corporation, et al. (Case No. 1:17-cv-00210) in the USDC for the Southern District of New York. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices.
On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29.
Take Action: if you suffered a loss in Ophthotech you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
First Western Ship Transits Strait of Hormuz Since Iran War Began
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Apple Turns 50: From Garage Startup to AI Crossroads
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 



